tag solid-tumour 
Pharmaceutical Technology
MAY 2, 2023
The most widely utilised IO class is immune checkpoint inhibitors (ICIs), which work by blocking the inhibitory interactions between tumour cells and T-cells, facilitating an anti-tumour immune response. There are more than 20 marketed ICIs with approvals across a very wide spectrum of solid tumour indications.
Pharmaceutical Technology
MAY 1, 2023
Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 5, 2023
But access to these treatments continues to remain limited due to high price tags and variable availability across regions. But while companies continue studying allogeneic CAR-T therapies, including for their coveted use in solid tumours, such advancements remain challenging. We also have the challenge of delivery.
The Pharma Data
AUGUST 18, 2020
The main focus of the deal is Dragonfly’s monovalent IL-12 immunoglobulin Fc fusion protein known as DF6002, which the company has been investigating in the treatment of both solid and blood cancers.
Drug Discovery World
JUNE 14, 2023
We are a cell therapy company that uses a very specific receptor to engineer T cells and administer these engineered T cells back to solid tumour patients. We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours.
pharmaphorum
JANUARY 5, 2021
Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.
pharmaphorum
APRIL 5, 2022
It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes.
Expert insights. Personalized for you.
130 
Let's personalize your content